HISTOPATHOLOGY
New system offers consistent, optimal IHC staining results
With increasing demands for advanced immunohistochemistry staining, a new system promises to deliver consistent, standardised results via a closed workflow which also places fewer demands on an already stretched laboratory workforce.
Advanced immunohistochemistry staining has become more and more complex over the last decades. The growing demand for more specific diagnosis and sub-diagnosis has increased the need for high quality
staining. Recent years have also seen the number of patient cases rising along with increased regulation such as IVDR, all this against a backdrop of staff shortages in laboratories. Launched in 2022, the Tissue-Tek Genie
from Sakura offers a completely new approach to staining quality and higher workloads.
It is not surprising that the workload of histopathology laboratories is increasing dramatically as the number of new cancer cases across Europe is estimated to grow by 22.5% over the next two decades, according to new estimates from the International Agency for Research on Cancer (IARC).1 In the UK this is being addressed by various initiatives such as the National Pathology Programme entitled Clinical Transformation Through Pathology Innovation.2
Today, healthcare providers
already operate under high pressure as current systems are exposed to more than their full capacity. This presents significant challenges to laboratories due to the nature of their work to manage complex tests, multiple workflows, and time-consuming sample preparation. In addition, errors arising from largely manual procedures cause extra work. For histopathology laboratories the implications of the growing burden of cancer are additional work pressures and need for new innovative solutions for automation and standardisation.
Quality and standardisation In 2023, the Nordic
A fully automated, true random access stainer for immunohistochemistry (IHC) and in situ hybridisation (ISH), the Tissue-Tek Genie Advanced Staining System enables standardisation of advanced staining of formalin-fixed, paraffin wax-embedded tissue..
WWW.PATHOLOGYINPRACTICE.COM OCTOBER 2024
Immunohistochemical Quality Control (NordiQC) Proficiency Testing Program concluded that 79% of immunohistochemistry (IHC) slides were accurate enough to make a diagnosis, that meant over a fifth were insufficient. The study – which analysed more than 30,000 IHC slides between 2017-2021 – found that 25% of the staining results in the general module, and between 8-11% in the breast cancer IHC module, were inadequate for diagnostic use.
37
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
